SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: European flags flap in the wind outside
Opinion
US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe
While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play its cards right to attract more studies.
June 16, 2025
 · 
6 min read
 · 
Craig Koch
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
RSV
Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology
Later this month, HHS Secretary Robert F. Kennedy Jr.'s revamped CDC vaccine advisory committee will discuss RSV vaccination guidelines for the newly approved patient group, high-risk adults 18 through 49. Analysts and other experts have warned that the new panel includes some who have documented anti-vaccine sentiments as well as those who have spoken out against mRNA technology specifically.
June 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Artificial intelligence
AstraZeneca Makes $5.3B AI Bet With China’s CSPC for Chronic Disease Pills
Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.
June 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Headshots of two men wearing suits
Vaccines
Two of Kennedy’s New ACIP Picks Were Paid Expert Witnesses in Merck Vaccine Cases
Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert participation in various vaccine-related cases against Merck.
June 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Bladder cancer
UroGen’s Bladder Cancer Drug Wins FDA Approval Over Adcomm’s Objections
The FDA’s Oncologic Drugs Advisory Committee narrowly voted against the approval of Zusduri, citing the lack of a completely randomized study to back up the application.
June 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Medical 2D illustration
Vaccines
As New CDC Vaccine Advisors Gear Up for First Meeting, Experts Ask, ‘Where’s Cassidy?’
Scientists and analysts express concern that the newly appointed ACIP members—which include known anti-vaxxers—could relitigate recommendations that have already been made. Many are imploring Sen. Bill Cassidy to step up.
June 12, 2025
 · 
4 min read
 · 
Heather McKenzie
Hiring collage showing HR checking applicant information
Job Trends
Hiring Outlook: Indiana, California Top 2 Hot Spots for Jobs in May
The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, based on BioSpace data. The two states had the most job postings live on BioSpace last month, with Indiana showing a 108% year-over-year increase.
June 12, 2025
 · 
4 min read
 · 
Angela Gabriel
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
BioNTech will get CureVac’s early-stage cancer assets, including its mRNA-based glioblastoma therapy currently in Phase I development. CureVac had previously sued BioNTech for copyright infringement related to mRNA vaccine technology.
June 12, 2025
 · 
3 min read
 · 
Tristan Manalac
Isolated hand photo on yellow background. Pink hand collage style. Bright pop art template with space for text. Creative minimalistic backdrop.
Lung cancer
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug
Nuvation Bio’s first approved product is Ibtrozi, a CNS-active ROS1 inhibitor that in pivotal studies showed high rates of treatment response in patients with non-small cell lung cancer.
June 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS